In neurodegenerative diseases, such as AD, and traumatic brain injury (TBI), ADE levels of the neurotoxic complement mediators C3b and C5b-9 are elevated relative to matched controls in part as a result of acquired concomitant deficiencies of complement regulatory membrane proteins CD55, CD59, and others11,12. Here, CD55 is linked to Alzheimer disease.